- Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Sarepta Therapeutics Announces Update on Regulatory Review of SRP-9001
- Sarepta Therapeutics Announces Positive Vote from U.S. FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy
- Sarepta Therapeutics Announces First Quarter 2023 Financial Results and Recent Corporate Developments
- Sarepta Therapeutics to Announce First Quarter 2023 Financial Results
- Sarepta Therapeutics Announces that the Date of the Advisory Committee Meeting for SRP-9001 will be May 12, 2023
- Sarepta Therapeutics Announces Advisory Committee Meeting will be Held for SRP-9001
Sarepta Therapeutics Inc (AB3A:FRA) closed at 115.20, -21.66% below its 52-week high of 147.06, set on Mar 08, 2023.
59.45Jun 17 2022147.06Mar 08 2023
Short selling activityProvided by S&P Global Market Intelligence
|Market cap||11.66bn USD|
|EPS (TTM)||-12.69 |
Data delayed at least 15 minutes, as of Jun 02 2023 07:00 BST.